M-136
甲氨蝶呤，1 X 100MG 溶液
1.0 mg/mL in methanol with 0.1N NaOH, ampule of 1 mL, certified reference material, Cerilliant®
登录 查看组织和合同定价。
选择尺寸
变更视图
关于此项目
经验公式（希尔记法）:
C20H22N8O5
化学文摘社编号:
分子量:
454.44
NACRES:
NA.24
PubChem Substance ID:
UNSPSC Code:
41116107
MDL number:
grade
certified reference material
Quality Level
form
liquid
feature
Snap-N-Spike®/Snap-N-Shoot®
packaging
ampule of 1 mL
manufacturer/tradename
Cerilliant®
concentration
1.0 mg/mL in methanol with 0.1N NaOH
technique(s)
gas chromatography (GC): suitable, liquid chromatography (LC): suitable
application(s)
pharmaceutical (small molecule)
format
single component solution
storage temp.
−20°C
SMILES string
O=C(C1=CC=C(N(C)CC2=NC3=C(N=C2)N=C(N)N=C3N)C=C1)NC(C(O)=O)CCC(O)=O
InChI
1S/C20H22N8O5/c1-28(9-11-8-23-17-15(24-11)16(21)26-20(22)27-17)12-4-2-10(3-5-12)18(31)25-13(19(32)33)6-7-14(29)30/h2-5,8,13H,6-7,9H2,1H3,(H,25,31)(H,29,30)(H,32,33)(H4,21,22,23,26,27)
InChI key
FBOZXECLQNJBKD-UHFFFAOYSA-N
General description
经认证的加标溶®液，用于通过HPLC或LC/MS进行治疗药物监测（TDM）分析。甲氨蝶呤用于癌症和自身免疫性疾病的治疗，是一种抗代谢和抗叶酸药物，由临床实验室监测，以确保患者保持在药物治疗范围内。Snap-N-Spike®格式允许实验室消除甲氨蝶呤等有害物质的称重操作，显著减少与处理急性毒性粉末有关的职业暴露危害，并提供在使用前将其加标到其选择的基质中的能力。
Legal Information
CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
CERTIFIED SPIKING SOLUTION is a registered trademark of Cerilliant Corporation
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany
Disclaimer
Supply conditions do not apply to the regions and states of Brazil: North, Northeast, Mato Grosso do Sul, Mato Grosso, and Rio Grande do Sul.
signalword
Danger
Hazard Classifications
Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - Met. Corr. 1 - STOT SE 1
target_organs
Eyes,Central nervous system
存储类别
3 - Flammable liquids
wgk
WGK 2
flash_point_f
51.8 °F - closed cup
flash_point_c
11 °C - closed cup
法规信息
危险化学品
此项目有
Joshua F Baker et al.
Annals of the rheumatic diseases, 73(11), 1968-1974 (2013-08-02)
To determine if early MRI measures predict X-ray progression at 1 and 2 years in a large RA trial cohort. This study included 256 methotrexate (MTX)-naïve RA patients from a randomised placebo-controlled trial of golimumab (GO-BEFORE). MRIs of wrist and 2nd-5th
J Westra et al.
Clinical and experimental immunology, 178(1), 40-47 (2014-06-04)
Rituximab (RTX) treatment in rheumatoid arthritis (RA) patients severely hampers humoral response after influenza vaccination as determined by haemagglutination inhibition assay (HI). It is not known whether HI reflects both immunoglobulin (Ig)M and IgG (subclass) influenza response, and whether IgM
Josef S Smolen et al.
Lancet (London, England), 383(9914), 321-332 (2013-10-31)
Biological agents offer good control of rheumatoid arthritis, but the long-term benefits of achieving low disease activity with a biological agent plus methotrexate or methotrexate alone are unclear. The OPTIMA trial assessed different treatment adjustment strategies in patients with early
全球贸易项目编号
| 货号 | GTIN |
|---|---|
| M-136-1ML | 04061833977071 |